Welcome to AGILE R100

Reliable biophysical characterization, at your fingertips.


The easy-to-learn AGILE R100 assay makes it simple to get dose-response curves and kinetic binding data earlier in the drug discovery process when you need it most. Built with highly sensitive, proprietary Field Effect Biosensing (FEB) technology, AGILE R100 enables detection even in crude samples using minimal volume, giving you control over the complete characterization of your biomolecules. 

Optimize leads with a novel label-free method and achieve measurements never before possible!

High sensitivity with AGILE R100


10 µL of sample

11-log dynamic range

Label-free measurements with AGILE R100


Label-free reduces

design complexity

AGILE R100 is a benchtop tool


Personal system

weighing 2 lbs.

AGILE R100 provides fast measurements in 2 minutes


Assay development

Sense in 2 minutes


AGILE R100’s open-pipetting design enables on-the-fly assay modification, vastly reducing assay development time.
See how it’s used in this 1:32 video!


Join us to learn more about the AGILE R100 orthogonal approach to biophysical characterization at one of these events!

Nanomedical Diagnostics2017 AAPS National Biotechnology Conference booth

2017 AAPS National Biotechnology Conference

Contact us for a complimentary guest pass to the 2017 AAPS National Biotechnology Conference in San Diego from May 1 through 3 to visit us at Booth 213 and learn more about biophysical characterization at your fingertips with AGILE R100!

Nanomedical Diagnostics 2018 Society for Laboratory Automation and Screening Conference booth

2018 Society for Laboratory Automation and Screening

We’ll be in Booth 332 at the 2018 the Society for Laboratory Automation and Screening (SLAS) conference in San Diego from Feb. 3-7 to launch AGILE R200, the only high-throughput biophysical data platform compatible with automated liquid handlers.


CRADA with the CDC to evaluate direct electronic detection for disease diagnostic systems.
DARPA grant awarded to develop hand-held drug therapeutic monitoring devices.
Mayo Clinic evaluating the diagnostic capabilities of field effect biosensor chips.
Stanford School of Medicine using AGILE R100 for in vitro kinetic binding data.